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ABSTRACT 
EXTREMELY SKEWED X-CHROMOSOME INACTIVATION IN JUVENILE 
IDIOPATHIC ARTHRITIS 
 
 
Chigdem Aydın Mustafa 
M.S. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Tayfun Özçelik 
July 2007, 74 Pages 
 
 
Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatic disease with 
female predominance and an incidence between 7-21/100,000. There are several 
explanations for the reason of disease development, such as environmental factors that 
trigger autoimmunity and genetic basis. The genetic basis of JIA is not well defined. It rarely 
manifests familial recurrence. But the monozygotic twin data suggest that there is a 
considerable genetic basis, which is likely to involve multiple epigenetic events.  It was 
proposed that a disturbance in mosaicism of females may cause autoimmune disease 
development. Recently, in our lab, an association between extremely skewed X-chromosome 
inactivation (XCI) patterns and female predisposition to autoimmunity was identified. Since 
JIA is thought to have an autoimmune etiology, we hypothesized that skewed XCI might 
play a role in the disease development. To determine XCI status, androgen receptor locus 
was analyzed by methylation sensitive Hpa II digestion followed by PCR by using of 72 
female patients diagnosed with JIA and 183 female controls, which comprised of newborns 
(n=91) and children with no history of an autoimmune condition (n=92). A male control (46, 
XY) was used for complete digestion in the analysis of XCI pattern. We expect to see an 
association between extremely skewed XCI and female predisposition to JIA.  
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ÖZET 
JÜVENĐL ĐDĐYOPATĐK ARTRĐT HASTALIĞINDA BOZUK X KROMOZOMU 
ETKĐNSĐZLEŞTĐRĐLMESĐ 
 
 
 
Chigdem Aydın Mustafa 
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Tayfun Özçelik 
Temmuz 2007, 74 Sayfa 
 
 
 
Jüvenil idiyopatik artrit (JĐA) çocukluk çağında görülen en sık romatolojik hastalıktır. 
Hastalığın görülme sıklığı 7–21/100.000 arasındadır ve genel olarak kız çocuklarında daha 
sık görülmektedir. Hastalığın oluşumu konusunda çevresel ve genetik etkenler olmak üzere 
farklı açıklamalar bulunmaktadır. JĐA’daki genetik etkenler tam anlamıyla bilinmemektedir. 
Tek yumurta ikizleri ile yapılan çalışmalar sonucu genetik etkenlerin varlığı saptanmıştır, 
ancak bu etkenler birçok epigenetik olayları kapsamaktadır. Daha önce kadınlardaki 
mozaizmin bozulmasının otoimmün hastalıklara neden olabileceği ileri sürülmüştür. Yakın 
zamanda laboratuarımızda gerçekleştirilen çalışmalar sonucunda bozuk X-
etkinsizleştirilmesi ve kadınların otoimmün hastalıklara yatkınlığı arasında bağlantı 
kurulmuştur. JĐA hastalığı da otoimmün bir hastalık olarak bilinmektedir. Bu nedenle bozuk 
X-etkinsizleştirilmesinin JĐA oluşumunda bir etkisi olabileceğini ileri sürüyoruz. 72 hasta ve 
183 sağlıklı kontrollerde X-etkinsizleştirilmesi statüsünü belirlemek için androjen reseptörü 
lokusu metillemeye duyarlı HpaII enzimi ile analiz edilmiştir. Kontrol grubu 91 yenidoğan 
ve 92 sağlıklı çocuktan oluşmuştur. X-etkinsizleştirilmesi analizinde tamamen X-
kromozomu kesilmesini göstermek üzere erkek kontrol (46, XY) kullanılmıştır. Burada 
bozuk X-etkinsizleştirilmesi ve JĐA’ ya kadın yatkınlığı arasında bir ilişki bulunmasını 
bekliyoruz. 
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  CHAPTER I: INTRODUCTION 
1.1 Juvenile Idiopathic Arthritis 
 
Juvenile idiopathic arthritis (JIA), which is the inflammation (cellular damage) of the 
synovium (the lining of joints), is the most prevalent pediatric rheumatic disease that is seen 
in children with onset before 16 years of age. JIA patients have swollen, painful joints (lasting 
more than six weeks), which may be stiff and difficult to move. The inflammation of the 
joints may result in damage to the bone and cartilage. This may cause possible changes in 
bone growth resulting in longer, shorter or bigger affected bones (Figure 1.1) (Cuccurullo, 
2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Leg-length discrepancy in a child with juvenile idiopathic arthritis (Rhodes, 1991) 
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Arthritis is best described by four major changes in the joints. The most common 
features of JIA involve the joint are inflammation, contracture, damage and alteration or 
change in growth.  Other symptoms are weakness in muscles and other soft tissues around 
involved joints.  It may also involve organs such as the skin, heart, lungs, liver, spleen, and 
eyes, producing extra-articular signs and symptoms (Cuccurullo, 2004; Petty et al., 2003). 
 
 
1.1.1.  Classification 
 
First proposed in 1994 and later revised in 1997, the term ‘juvenile idiopathic arthritis’ 
(JIA) (Petty et al., 1998; Petty et al., 2003; Petty et al., 2004) was used instead of the 
American term ‘juvenile rheumatoid arthritis’ (JRA) as defined by American College of 
Rheumatology (ACR) (Brewer et al., 1977) and the European classification ‘juvenile chronic 
arthritis’ (JCA) as defined by the European League Against Rheumatism (EULAR) (Wood et 
al., 1978). Because the American and European classifications of the disease were confusing 
(Table 1.1), it was difficult to use them interchangeably (disease duration is 6 weeks for ACR, 
while it is 12 weeks for EULAR). In an effort to improve research and treatment, the 
International League Against Rheumatism (ILAR) has devised a unifying set of international 
criteria, using the term ‘juvenile idiopathic arthritis’. The word ‘idiopathic’ means ‘of 
unknown cause’. This classification is gaining favor among researchers, but is not yet 
universally used.  
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Table 1.1. Comparison of the classification systems of arthritis in children 
 
 
  Classification        ACR       EULAR                   ILAR 
____________       _____                       _______                                _____ 
  Designation          JRA        JCA                   JIA 
 
     
  Types          Systemic       Systemic                   Systemic 
        Pauciarticular       Pauciarticular                 Oligoarticular 
        Polyarticular        RF-negative polyarticular     RF-negative polyarthritis 
     RF-positive polyarticular      RF-positive polyarthritis 
     Psoriatic       Psoriatic 
     JAS        Enthesitis-related 
                  Undefined 
 
 
ACR=American College of Rheumatology; EULAR=European League against Rheumatism; 
ILAR=International League of Associations for Rheumatology; JRA= juvenile rheumatoid arthritis; 
JCA= juvenile chronic arthritis; JIA= juvenile idiopathic arthritis; JAS= juvenile ankylosing 
spondylitis (Petty et al., 2003). 
 
 
The ILAR classification aims to both unify the previous classifications to minimize 
international differences in disease definition and to identify clinically homogenous disease 
subgroups within the term JIA (Petty et al., 1998).  
 
 
1.1.2. Types 
 
According to ILAR, the major subtypes of JIA are oligoarticular JIA, which may be 
persistent or extended, polyarticular rheumatoid factor (RF)–negative JIA, polyarticular RF-
positive JIA, systemic JIA, enthesitis-related arthritis (ERA), psoriatic JIA, or a classification 
of “other JIA” when the criteria for more than one subtype of JIA or none of the criteria were 
met (Petty et al., 1998). 
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1.1.2.1. Oligoarticular JIA 
 
Oligoarthritis affects four or fewer joints during the first 6 months of disease. It is the 
most common type, affecting about 50% of all children with JIA, and mostly seen in females. 
In the ILAR classification, children who have psoriasis/a family history of psoriasis, a human 
leukocyte antigen (HLA) B27-associated disease in a first-degree relative, and a positive 
rheumatoid factor (RF) test are excluded from the oligoarthritis category (Petty et al., 1998). 
 
This form of JIA is not seen in adults, and it is characterized by asymmetric arthritis, 
early age of onset (before 6 years of age), female predominance, high frequency of positive 
antinuclear antibodies (ANAs), and high risk of iridocyclitis (uveitis), which is an eye 
inflammation. It is more common in the larger joints, like the knees, ankles or elbows, but can 
also affect wrists, fingers and toes (Cuccurullo, 2004; Ravelli et al., 2007). 
 
According to the ILAR classification, there are two categories in the oligoarthritis 
subtype: persistent oligoarthritis, in which the disease consists of four or fewer joints, and 
extended oligoarthritis, in which arthritis extends to more than four joints after the first 6 
months of disease (Petty et al., 1998; Ravelli et al., 2007). 
 
 
1.1.2.2.  Polyarticular JIA 
 
Polyarticular arthritis affects 35% children with JIA, more girls than boys. Symptoms 
include swelling or pain in 5 or more joints. This kind of JIA usually involves small joints of 
the hands and feet (Figure 1.2). Large joints, such as knees, wrists, elbows, and ankles are 
also involved in association with small joints. Additionally, the joints of the neck (cervical 
spine) and jaw (temporomandibular joints) may also be affected. In addition, a low-grade 
fever and tiredness may appear. Polyarticular JIA is often symmetrical.  There are two types 
of polyarticular JIA: rheumatoid-factor-positive and rheumatoid-factor-negative polyarthritis 
(Cuccurullo, 2004; Ravelli et al., 2007).  
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Figure 1.2 Radiographs of normal hand (left) and arthritic hand (right). (Arrows denote loss 
of normal axial alignment) (Rhodes, 1991) 
 
 
1.1.2.2.1. Rheumatoid-factor-positive polyarthritis 
 
This disease, comprises 10% of all patients with JIA, and is characterized by age of 
onset greater than 11 years of age with female predominance (Cuccurullo, 2004). It is the 
same as adult RF-positive rheumatoid arthritis, except the differences in disease phenotype 
between children and adults, which are related to the effect of the disease in an individual 
whose skeleton is still growing. It is mainly seen in adolescent girls (Cuccurullo, 2004; 
Ravelli et al., 2007).  
 
It is characterized as a symmetrical polyarthritis that affects small joints of the hands 
and feet (Figure 1.3) (Ravelli et al., 2007).   
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Figure 1.3 Symmetric polyarthritis affecting the metacarpophalangeal, proximal and distal 
interphalangeal, and radiocarpal joint (Ravelli et al., 2007).  
 
 
1.1.2.2.2. Rheumatoid-factor-negative polyarthritis 
 
This disease is less defined than RF-positive polyarthritis, and is the most 
heterogeneous subtype (Ravelli et al., 2007). It affects 25% of all patients with JIA 
(Cuccurullo, 2004). There are at least three subsets of RF-negative polyarthritis. The first 
form resembles early-onset oligoarticular juvenile idiopathic arthritis with the characteristics 
of asymmetric arthritis, early age of onset, female predominance, frequent positive ANAs, 
and increased risk of iridocyclitis, except for the number of joints affected in the first 6 
months of disease (Martini, 2003; Ravelli et al., 2007). The second subset is similar to adult 
onset RF-negative rheumatoid arthritis, with characteristics of symmetric synovitis of large 
and small joints, onset in school age, and negative ANA (Ansell, 1987; Ravelli et al., 2007). 
The third form is known as dry synovitis, which shows negligible joint swelling but stiffness, 
flexion contractures (Figure 1.4). This subset is often poorly responsive to treatment and 
could follow a destructive progress (Ostrov, 2004; Ravelli et al., 2007).  
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Figure 1.4.  Flexion contracture in child with juvenile idiopathic arthritis (Rhodes, 1991). 
 
 
1.1.2.3   Systemic JIA 
  
It usually begins in early childhood. Researchers sometimes call this Still’s disease. 
This type accounts for about 10-20% of cases of JIA. Systemic arthritis affects both boys and 
girls almost equally. There may be fever and a rash (Figure 1.5), but joint involvement may 
not be apparent at first although the child's behavior may indicate joint pain. Fever occurs 
suddenly and spikes to 39.4°C or higher once or twice daily, usually in the late afternoon. It 
then rapidly returns to normal or subnormal. It is this discontinuous spiking fever pattern that 
helps to differentiate the disease from other inflammatory disorders. Other signs and 
symptoms may include hepatosplenomegaly (enlargement of the liver and spleen), 
lymphadenopathy (lymph node involvement), pleuritis (or pleurisy -- inflammation of the 
lining of the lungs or thoracic cavity), pericarditis (inflammation of the sac enclosing the 
heart), myocarditis (inflammation of the muscular walls of the heart), and nonspecific 
abdominal pain (Cuccurullo, 2004; Ravelli et al., 2007). Anemia and weight loss may also 
occur (Martini et al., 1994; Ravelli et al., 2007).  
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Figure 1.5 Typical rash of systemic-onset disease in an 8-year-old child (Ravelli et al., 2007). 
 
 
1.1.2.4.   Enthesitis-related arthritis 
 
Enthesitis is an inflammation of the entheses, the location where a bone has an 
insertion to a tendon or a ligament. Enthesitis-related arthritis, which is characterized by the 
association of enthesitis and arthritis, mainly affects male patients after the age of 6 years. 
Most patients are HLA-B27 positive, and the joints of the lower extremities are affected. Hip 
involvement is common at disease presentation, resembling oligoarthritis (Petty et al., 2001; 
Petty et al., 2003). Enthesitis-related arthritis is often remitting and can be mild. About half of 
patients have four or fewer joints affected throughout the entire course of the disease (Petty et 
al., 1998; Petty et al., 2003; Ravelli et al., 2007). 
 
 
1.1.2.5.   Psoriatic arthritis 
 
According to ILAR, in order to diagnose juvenile psoriatic arthritis, arthritis and 
psoriatic rash need to be present. If a rash is absent, the presence of arthritis and any two of 
the following: family history of psoriasis in a first-degree relative; dactylitis (sausage-shaped 
swelling of the fingers and toes, that can be painful); and nail pitting. The symptoms are 
similar to the subset of RF-negative polyarthritis, and oligoarthritis. The main difference is 
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that patients with psoriatic arthritis have a greater frequency of dactylitis and of arthritis that 
affects both small and large joints than do children with oligoarthritis (Petty et al., 1998; 
Ravelli et al., 2007). 
 
 
1.1.2.6   Undifferentiated arthritis 
 
Undifferentiated arthritis does not represent a separate subset, but includes patients 
who do not satisfy inclusion criteria for any category, or who meet the criteria for more than 
one (Petty et al., 2004; Ravelli et al., 2007).  
 
 
1.1.3.   Prevalence and incidence 
 
The incidence and the prevalence of the disease differ among different ethnicity (Table 
1.2). The prevalence of a disease in a statistical population is defined as the total number of 
cases of the disease in the population at a given time, or the total number of cases in the 
population, divided by the number of individuals in the population, while the incidence is the 
number of new cases of a disease during a given time interval, usually one year. 
 
 
 
Table 1.2  Comparison of incidence and prevalence in different populations 
 
 
Country  Pre.   Inc.   Reference 
 
 
Canada  -   4.08/100,000  Malleson et al., 1996 
Sweden  56/100,000  12/100,000  Andersson et al., 1987 
Norway  148.1/100,000  22.6/100,000  Moe et al., 1998 
Finland  -   19.6/100,000  Kunnamo et al., 1986 
Germany  14.8/100,000  6.6/100,000  von Koskull et al., 2001 
Costa Rica  34.9/100,000  6.8/100,000  Arguedas et al., 1998 
 
 
Pre= Prevalence, Inc= Incidence. 
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 The frequency of the subtypes differs. There is female predominance, except in the 
systemic and enthesitis-related arthritis (Table 1.3). In systemic arthritis female-male ratio is 
equal. In enthesitis-related arthritis, there is male predominance.   
 
 
Table 1.3 International League of Associations for Rheumatology (ILAR) categories of 
juvenile idiopathic arthritis 
 
 
(Ravelli et al., 2007) 
 
 
1.1.4. Causes 
 
The cause of JIA is not well-understood. It is believed that JIA is caused by a 
combination of factors, including genetic factors that make a child's immune system more 
likely to react inappropriately, an overly active immune system that inappropriately attacks 
joint tissues, and viral or bacterial infections that may trigger the autoimmune process 
(Cuccurullo, 2004).  
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1.1.4.1.   Associated Genes 
  
 JIA rarely manifests familial occurrence. In the USA total number of affected sibling 
pairs (ASP) has been estimated to be ~300-400.  The National Institute of Arthritis and 
Musculoskeletal and Skin Diseases has sponsored a research for JIA-affected sibling pairs. 
Initial analysis showed that 63% of 71 ASPs were concordant for gender and 76% for onset 
type (Moroldo et al., 1997).  The study also provided the first estimate of the sibling 
recurrence risk (λs) for JIA: 15, a value similar to type 1 diabetes. Such a high λs is indicative 
of a factor shared between sibling, genetic or environment.  Researchers from Finland 
estimated the λs of JIA to be ~20, by using 41 JIA multicase families with 88 affected 
siblings. In the study, it was calculated that a monozygotic twin of a JIA patient had a relative 
risk (RR) for developing JIA of about 250 (Savolainen et al., 2000; Borchers et al., 2006; 
Glass et al., 1999). These data suggest that there is a considerable genetic basis in JIA, but 
this genetic basis is complex (Reviewed in Borchers et al., 2006).   
 
 There are both MHC-associated and Non-MHC genes that are found to be associated 
with JIA.  The class I gene, HLA-B27, was the first HLA association found in JIA. It is found 
that HLA-B27 is a risk factor for oligoarthritis, particularly in older male patients 
(Rachelefsky et al., 1974).  
 
 The class II genes HLA-DR1 and HLA-DR4, have been reported to increase risk for 
polyarthritis. DR4 has a particularly high association with RF–positive polyarticular JIA in 
older children. Homozygosity for DR4 may carry an increased risk of disease. DR1 is 
associated with oligoarthritis that converts to a polyarthritis in younger patients, as well as 
contributing risk for polyarticular disease in older children (Nepom et al., 1984; Glass et al., 
1999).  
 
 Table 1.4 lists the non-MHC genes and chromosome regions that have been reported 
to be associated with JIA (Glass et al., 1999). In general, the odds ratios are low and case-
control studies have not been as reproducible as HLA association studies (Glass et al., 1999).  
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Table 1.4. Non-HLA genes/loci in juvenile idiopathic arthritis 
 
 
Polymorphism/chromosome region      Reference 
 
 
IgA deficiency        Cassidy et al., 1977 
Complement deficiency       Glass et al., 1980 
α1-antitrypsin         Aranaud et al., 1977 
Amyloid P component       Woo et al., 1987 
IL-1α promoter        McDowell et al., 1995 
TNFα/ß         Epplen et al., 1995 
TCR Vß6.1 null gene        Maksymowych et al., 1992 
IL-6 promoter        Fishman et al., 1998 
IL-10          Crawley et al., 1999 
Chromosome 22        Sullivan et al., 1997 
 
IL = interleukin; TNF = tumor necrosis factor; TCR = T cell receptor (Glass et al., 1999).
  
 
1.1.4.2.   Antibodies 
 
JIA is an autoimmune disease, and a wide variety of auto-Abs has been described in 
patients with JIA (Table 1.5). None of these is specific to JIA and only rheumatoid factor 
(IgM RF) and antinuclear antibodies (ANA) are routinely used to provide serological support 
for the diagnosis of JIA.  
 
ANA are detected in ~30–50% of patients with JIA (Berntson et al., 2003; Flatø et al., 
1998; Serra et al., 1999; Kotaniemi et al., 1999), with prevalence estimates in the individual 
subtypes ranging from 38% to 85% in oligoarthritis, ~30–50% in polyarthritis and 0–17% in 
systemic onset disease (Al-Matar et al., 2002; Moroldo et al., 2004). ANA positivity is one of 
the most important risk factors for uveitis (Packham et al., 2002; Kotaniemi et al., 2001), but 
is not significantly associated with the development of complications and visual outcome 
(Cabral et al., 1994).  
 
One of the specific targets of ANA in JIA is the 45 kDa DEK nuclear antigen (Szer et 
al., 1994; Murray et al., 1997), a DNA-binding protein. It was shown to bind specifically to 
the conserved Y-box regulatory sequences in the human leukocyte antigens (HLA) 
DQA1*0101 and DQA1*0501 (Adams et al., 2003), which is known as a susceptibility allele 
for oligoarticular JIA (Thomson et al., 2002; Borchers et al., 2006).  
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2%- 12% of patients with JIA are positive for IgM RF, including up to 21% of patients 
with polyarticular disease, 9% of patients with oligoarthritis and 0 - 15% of patients with 
systemic onset arthritis according to the EULAR and ACR criteria. Rheumatoid factor is an 
antibody directed against the Fc fragment of IgG. (Minden et al., 2000; Kotaniemi et al., 
1999).  
 
 In more recent studies; an ELISA, based on a cyclic citrullinated peptide (CCP) for 
detection of antibodies against citrullinated proteins in JIA patients, was used. Two of the 
studies reported significantly high frequencies of anti-CCP in RF-positive polyarthritis 
patients (73% and 57%, respectively) (van Rossum et al., 2003; Ferucci et al., 2005; Borchers 
et al., 2006). In a study, in which 3 synthetic citrullinated peptides and 2 different ELISA kits 
were used, frequencies of anti-CCP antibodies of up to 77% in patients with JIA overall, 93% 
in RF-negative polyarthritis, 84% in oligoarthritis and 62% in systemic arthritis patients were 
reported (Low et al., 2004; Borchers et al., 2006). 
 
 
Table 1.5 Antibodies described in JIA patients 
Antibodies      Reference 
ANA    Berntson et al., 2003; Flatø et al., 1998; Serra et al., 1999;   
Kotaniemi et al., 1999 
RF    Minden et al., 2000; Kotaniemi et al., 1999 
Antikeratin, Antifilaggrin,       Nesher et al., 1992; Gabay et al., 1993; Hromadnikova et al., 2001 
Anticitrullinated fibrin,        
Anti-Sa          
Anti-CCP              van Rossum et al., 2003; Ferucci et al., 2005; Low et al., 2004 
ANA= antinuclear antibodies; RF= rheumatoid factor; Sa= citrullinated vimentin; CCP=cyclic 
citrullinated peptide (Borchers et al., 2006). 
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1.2   Autoimmunity 
 
Autoimmunity is the failure of an organism to recognize its own constituent parts 
(down to the sub-molecular levels) as "self", which results in an immune response against its 
own cells and tissues. Any disease that results from such an aberrant immune response is 
termed an autoimmune disease (Janeway et al., 2005).  
 
All individuals are tolerant of their own potentially antigenic substances, and failure of 
self tolerance is the fundamental cause of autoimmunity. The mechanisms of self tolerance 
have been worked out in considerable detail in animal models, and are best understood for 
CD4+ T cells (Figure 1.6). Self tolerance can be divided into central tolerance and peripheral 
tolerance. In central tolerance, immature lymphocytes that happen to recognize self antigens 
in generative lymphoid organs (the bone marrow for B cells and the thymus for T cells) die by 
apoptosis; in peripheral tolerance, mature self-reactive lymphocytes encounter self antigens in 
peripheral tissues and are killed or shut off. The principal mechanisms of peripheral tolerance 
are anergy (functional unresponsiveness), deletion (apoptotic cell death), and suppression by 
regulatory T cells. 
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Figure 1.6  Self tolerance (Goodnow et al., 2005). a, The cell is deleted through induction of 
cell death. b, The receptor is edited to one that is less self-reactive. c, Biochemical or gene-
expression changes intrinsically dampen the self-reactive receptor’s ability to activate the cell. 
d, The ability of self-reactive cells or antibody to cause autoimmunity is limited by using 
extrinsic suppression and by limiting essential growth factors, costimuli and inflammatory 
mediators. 
 
 
 
1.2.1  Cause of Autoimmunity 
 
Autoimmune diseases develop when self-reactive lymphocytes escape from tolerance 
and are activated. Although the mechanisms by which this occurs are not entirely known, 
autoimmunity is thought to result from a combination of genetic variants, acquired 
environmental triggers such as infections, and stochastic events (Janeway et al., 2005).  
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1.2.1.1.   Genes associated with autoimmunity 
 
1.2.1.1.1. AIRE 
 
AIRE (autoimmune regulator) was identified as the gene that is mutated in 
autoimmune polyendocrine syndrome (APS-1) — a disorder that manifests as autoimmune 
attack against multiple endocrine organs, the skin and other tissues (Bjorses et al., 1998). 
 
The mouse homologue of the gene has been knocked out, and the AIRE protein shown 
to be responsible for the thymic expression of some antigens that are expressed at high levels 
in different peripheral tissues. In the absence of thymic expression, T cells specific for these 
antigens escape negative selection (central tolerance), enter the periphery and attack the target 
tissues ( Anderson et al., 2002; Liston et al., 2003).  
 
 
1.2.1.1.2. CTLA4 
 
Cytotoxic T lymphocyte antigen 4 (CTLA4; CD152) is an inhibitory receptor 
expressed by T cells that recognizes the costimulatory molecules B7-1 (CD80) and B7-2 
(CD86), the ligation of which shuts off T-cell responses and promotes long-lived anergy 
(Salomon and Bluestone, 2001). CTLA4 works by competitively blocking the engagement of 
the activating receptor CD28 (by CD80 or CD86), and by transducing inhibitory signals; the 
latter probably involves tyrosine and serine/threonine phosphatase activation (Baroja et al., 
2002). 
 
 
1.2.1.1.3. FOXP3 
 
FOXP3 (encoding a transcription factor of the forkhead family) is a striking example 
of a gene whose role in autoimmunity has been revealed by the confluence of animal studies 
and studies of a quite rare human disease. CD4+CD25+ regulatory T cells, now established as 
major controllers of immune responses to self and other antigens (Sakaguchi, 2004), were 
shown to express high levels of FOXP3. Three groups demonstrated that induced knockout or 
spontaneous mutation of the mouse Foxp3 gene led to a systemic autoimmune disease 
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associated with the absence of CD4+CD25+ regulatory T cells (Hori et al., 2003; Fontenot et 
al., 2003; Khattri et al., 2003). 
 
 
1.2.1.1.4.  PTPN22 
 
PTPN22 gene maps to chromosome 1p13.3–p13.1 and encodes a lymphoid specific 
phosphatase (Lyp). Lyp is an intracellular PTP and physically bound through proline-rich 
motif to the SH3 domain of the Csk kinase, which is an important suppressor of kinases that 
mediate T-cell activation (Cohen et al., 1999). Recently, it was shown that PTPN22 1858C-
>T SNP may play role in autoimmunity (Bottini et al., 2004; Begovich et al., 2004). The 
PTPN22 1858C->T SNP changes the amino acid at position 620 from an arginine (R) to a 
tryptophan (W) and disrupts the interaction between Lyp and Csk, avoiding the formation of 
the complex and, therefore, the suppression of T-cell activation (Cloutier et al., 1999). 
 
 
1.2.1.2.   Molecular Mimicry 
  
Molecular mimicry is defined as the theoretical possibility that sequence similarities 
between foreign and self-peptides are sufficient enough to result in the cross-activation of 
autoreactive T or B cells by pathogen-derived peptides (Janeway et al., 2005). Upon the 
activation of B or T cells, it is believed that these “peptide mimic” specific T or B cells can 
cross-react with self-epitopes, thus leading to autoimmunity (Kohm et al., 2003). Assuming 
five to six amino acid residues are used to induce a monoclonal antibody response, the 
probability of 20 amino acids occurring in six identical residues between two proteins is 206 
or 1 in 64,000,000. However, there has been evidence shown and documented of many 
molecular mimicry events (Oldstone, 1998).  
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1.2.1.3.   Female Predominance in autoimmunity 
 
1.2.1.3.1.  Hormones 
 
In most of the autoimmune diseases, such as autoimmune thyroiditis, systemic lupus 
erythematosus, and scleroderma there is female predominance, 3-10 fold more affected 
females (Whitacre, 2001). There are several explanations for this predominance. One of them 
is sex hormones. (Lockshin, 2002). The inhibitory effects of sex steroids on autoimmune 
diseases were initially demonstrated in experimental autoimmune thyroiditis induced in 
guinea pigs and rats by thyroid extract adjuvant administration (Kappas et al., 1963). Both 
testosterone and estrogen at moderately high doses suppressed autoimmune thyroiditis in 
guinea pigs. Similar effects of testosterone, but not estrogen, were noted in autoimmune 
thyroiditis induced in rats. 
 
 
1.2.1.3.2  Chimerism 
 
Another possible explanation for the female predominance in autoimmune diseases is 
chimerism. Microchimerism resulting from transplacental cells (cell passage from child to 
mother, or in some instances, mother to child) was considered responsible for autoimmune 
diseases, including SSc (Mullinax, 1993, Nelson,1996). Fetal DNA and cells were identified 
in some women with SSc (Nelson, 1996; Mullinax et al., 1996; Nelson et al., 1998; Artlett et 
al., 1998), raising the possibility that microchimerism play a role in autoimmune diseases. 
Although these findings are really interesting, microchimerism in SSc could be secondary to 
the underlying disease, because it offers no explanation for the occurrence of the disease in 
men or in women who have had no children (Welsh, 1998). 
 
 
1.2.1.3.3.  Skewed XCI 
 
Disturbed X-inactivation is another explanation for the female predominance in 
autoimmune diseases (Kast, 1977; Stewart, 1998; Chitnis et al., 2000). As a result of X-
inactivation, the X-chromosome inherited from either parent is silenced at random, and 
normal women are thus a mosaic of 2 cell populations. Therefore, it is reasonable that skewed 
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XCI could lead to the escape of X-linked self antigens from presentation in the thymus or in 
other peripheral sites that are involved in tolerance induction, and loss of T cell tolerance. 
High frequency of skewed X-inactivation has been observed in breast and ovarian cancers 
(Kristiansen et al., 2002, Buller et al., 1999), and in women with recurrent spontaneous 
abortions (Lanasa et al., 1999, Sangha et al., 1999). Recently it was shown that there are high 
numbers of scleroderma patients that have extremely skewed inactivation in the peripheral 
blood (Ozbalkan et al., 2005). Also, in AITD patients, extremely skewed inactivation was 
observed in peripheral blood (Ozcelik et al., 2006).   
 
 
1.3   X-Inactivation 
 
1.3.1  History 
 
In 1961 Mary Lyon proposed a hypothesis to explain several unexpected results in her 
analysis of mutations affecting the coat color of female mice. She suggested that only one of 
the two X-chromosomes functioned in each cell of a female, and the other became inactive; 
because either parental chromosome could be inactive, females would be mosaics (Lyon,  
1961). She also suggested that the X-inactivation event occurred early in development. 
Therefore, each cell clone formed large patches of different color.  
 
At that time, Ernest Beutler made a similar proposal to explain that females inactivate 
one X-chromosome in order to maintain dosage parity with the single X-chromosome in 
males (dosage compensation). Beutler and colleagues formulated the XCI hypothesis using 
studies of the human X-chromosome gene glucose 6-phosphate dehydrogenase (G6PD) 
(Beutler et al., 1962). They found that in females, G6PD activity was not twice that of males 
and postulated a dosage compensation mechanism. Using a mixture of male cells with 
deficient G6PD activity and normal G6PD activity, Beutler and colleagues measured G6PD 
activity (by glutathione stability) and compared it to the response of female erythrocytes. 
They concluded that intermediate activity in females was probably due to the same 
mechanism as in the mixture of male normal and G6PD activity deficient erythrocytes. 
 
After these proposals, a hypothesis came from Ohno, Hauschka, and Makino who 
demonstrated, first in mice then in humans, that Barr bodies (Barr et al., 1949) did not consist 
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of portions of two X-chromosomes in opposition to each other. Rather, each Barr body was a 
single X-chromosome (Ohno et al., 1960, Ohno et al., 1961). Until that time, many believed 
that the Barr bodies, which were called sex chromatin body at that time, were structures 
formed by the crossing of the two X-chromosomes in the cell.  
 
 
1.3.2.  Mechanism 
 
Normally, in eutherian mammals, X-inactivation is a random process. By contrast, in 
marsupials, the X-chromosome coming from the father is always inactivated (Cooper et al., 
1971). More recently, it was shown that eutherian mammals also have imprinted XCI, as 
marsupials. But this is limited to extra-embryonic tissues-the placenta (Figure 1.7) (Takagi 
and Sasaki, 1975). Mouse cells undergo an early, imprinted inactivation of the paternally-
derived X-chromosome in four-cell stage embryos. The extraembryonic tissues (which give 
rise to the placenta and other tissues supporting the embryo) retain this early imprinted 
inactivation, and thus only the maternal X-chromosome is active in these tissues.  In the early 
blastocyst, this initial, imprinted X-inactivation is reversed in the cells of the inner cell mass 
(which give rise to the embryo), and in these cells both X-chromosomes become active again. 
Each of these cells then independently randomly inactivates one copy of the X-chromosome. 
This inactivation event is irreversible during the lifetime of the cell, so all the descendants of a 
cell which inactivated a particular X-chromosome will also inactivate that same chromosome. 
This leads to mosaicism. X-inactivation is reversed in the female germline, so that all ova 
contain an active X-chromosome.  
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Figure 1.7  Imprinted XCI (Huynh and Lee, 2004). 
 
 
Random X-inactivation has often been described as a multistep process involving 
choice of the active X-chromosome (Xa), initiation and spread of silencing on the inactive X-
chromosome (Xi), and subsequent maintenance of the Xi’s silent state (Chow et al., 2005). 
 
Sequences at the X-inactivation center (XIC), present on the X-chromosome, control 
the silencing of the X-chromosome. The hypothetical blocking factor is predicted to bind to 
sequences within the XIC (Russell, 1963; Therman et al., 1974). 
 
In 1991 a gene located within the XIC, the Xi-specific transcript was discovered 
(Borsani et al., 1991; Brockdorff et al., 1992; Brown et al., 1992, Brown, 1991). XIST is a 
gene transcribed from the Xi and not from Xa in somatic cells. No significant open reading 
frame has been identified, suggesting that XIST does not encode a protein. Xist has 
subsequently been shown to be the pivotal player in choice of which X-chromosome remains 
active, and in the spread of silencing on the future Xi (Marahrens et al., 1998). The Xist RNA 
works only in cis; that is, on the chromosome that made it.   
 
In 1999, several groups reported the identification of antisense transcription through 
the Xist locus in embryonic stem cells. The transcript, named Tsix in recognition of it being 
antisense to Xist, was found to initiate at a major transcription start site 13 kb downstream of 
the Xist 3’ end, and to extend across Xist into its promoter region. Subsequently, a minor Tsix 
promoter has been identified, and mature Tsix transcripts of up to 4 kb have been shown to be 
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produced by splicing. Like Xist, Tsix has no significant open reading frame and is not thought 
to encode a protein (Lee et al., 1999). 
 
In general, the women are mosaics of inactive X-chromosome. In some cases, skewed 
XCI might occur.  There are two main reasons of skewed XCI: primary and secondary. A 
mutation in Xic (X-inactivation-center), or in XIST (X-inactive-specific transcript) is primary 
cause. The secondary causes are deleterious X-linked mutations, X-chromosome 
rearrangements, aging, twinning or monoclonal expansion of cells (reviewed by Brown, 
1999).  
 
How skewed XCI could lead to self recognition failure is not well understood in a 
hypothesis, it is thought that skewed XCI can yield a situation in which self-antigens on one 
X-chromosome may fail to be expressed at sufficiently high levels in the thymus, or in other 
peripheral sites that are involved in tolerance induction, but may yet be expressed with a high 
frequency in other peripheral tissues and blood cells. Theoretically, some females may be 
predisposed to express X-linked antigens in the periphery to which they have been 
insufficiently tolerized (Brix et al., 2005).    
 
 
1.4.  Aim and Strategy 
 
 Most of the autoimmune diseases have high female predominance (Whitacre, 2001). 
Although the female prevalence is often attributed to the effect of estrogen, it is stated that 
other sex differences might have as much or more relevance to autoimmune disease, that is X-
inactivation (Stewart, 1998).  Recently, it has been shown that high proportion of scleroderma 
and AITD patients has extremely skewed X-inactivation in their blood cells (Ozbalkan et al., 
2005; Ozcelik et al., 2006).   
 
 JIA is an autoimmune disease, with unknown cause. Like other autoimmune diseases 
it has female predominance. Here we hypothesize that skewed XCI might play a role in the 
pathogenesis of JIA.  In order to test our hypothesis, we analyzed the methylation status of a 
highly polymorphic CAG repeat in the androgen receptor (AR) gene.  In this study we used 
JIA patients within the subgroups that have female predominance: oligoarthrits and 
polyarthritis.  
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CHAPTER II: MATERIALS AND METHODS 
2.1.  MATERIALS 
 
2.1.1.  Patient and Control samples 
 
JIA patients were referred to Bilkent University, Faculty of Science, Molecular 
Biology and Genetics Department (Ankara, Turkey) by collaborating physicians at Hacettepe 
University, Faculty of Medicine, Department of Pediatrics, Pediatric Nephrology Unit 
(Ankara, Turkey). The patients were diagnosed to have oligoarticular or polyarticular JIA. 
Blood samples were collected in tubes containing EDTA, with the consent forms signed.  
 
 
2.1.2. Primers 
 
The primers used in polymerase chain reaction (PCR) were synthesized by IONTEK (Bursa, 
Turkey). 
 
The primer sequences are:  primer 1, 5'- GTCCAAGACCTACCGAGGAG -3';  
primer 2, 5'- CCAGGACCAGGTAGGCTGTG -3' 
  
 
2.1.3. Enzymes 
 
Taq DNA polymerases were supplied from MBI Fermentas Inc. (Amherst, NY, USA). RsaI  
and methylation sensitive HpaII was supplied from Fermentas, Amh, NY, USA.  
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2.1.4.  Thermal cyclers 
 
For PCR reactions, the thermal cycler The GeneAmp System 9600 (Perkin-Elmer, USA) was 
used. 
 
 
2.1.5.  Chemicals, and kits 
 
Table 2.1.  Chemicals, reagents, and kits used in the experiments 
 
Reagent Supplier Used for 
 
Agarose  Basica LE, EU Agarose Gel electrophoresis 
Bisacrylamide  Sigma, St. Louis, MO, USA Polyacrylamide Gel 
Electrophoresis 
Bromophenol Blue  Sigma, St. Louis, MO, USA Gel Electrophoresis 
Ethanol EtOH  Merck, Frankfurt, Germany  
Ethidium Bromide EtBr  Sigma, St. Louis, MO, USA Gel Electrophoresis 
Proteinase K  Appligene-Oncor, USA Nucleic Acid Extraction 
TEMED  Carlo Erba, Milano, Italy Polyacrylamide Gel 
Electrophoresis 
APS  Carlo Erba, Milano, Italy Polyacrylamide Gel 
Electrophoresis 
EDTA pH 8.0  Carlo Erba, Milano, Italy TAE 
Nucleospin® Blood kit 
 
Macherey-Nagel Inc., PA, 
USA 
 
DNA isolation 
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2.1.6. Standard solutions and buffers 
 
1X TAE (Tris-acetic acid-EDTA):   40mM Tris-acetate, 2 nM EDTA, pH 8.0 
 
Ethidium bromide:     10mg/ml in water (stock solution) 
       30 ng/ml (working solution) 
 
Agarose Gel Loading Buffer (6X):   15% ficoll 
0.05% bromophenol 
0.05% xylene cyanol 
 
Acrylamide:Biacrylamide Stock Solution (%30): 29.5 gr acrylamide 
0.44 gr bisacrylamide 
100 ml with ddH2O  
 
2.1.7. Nucleic acids 
 
DNA marker, pUC Mix8 was supplied from MBI Fermentas, Amh, NY, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Sizes of the fragments of PUC mix marker, 8 and appearance on both agarose and 
polyacrylamide gel electrophoresis (MBI Fermentas web site) 
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2.2  METHODS 
 
2.2.1. Sample collection 
 
Blood was obtained from JIA patients and controls, and collected in tubes containing 
EDTA. They were divided into 1 ml aliquots in 1.5 ml eppendorf tubes. 200 µl of blood was 
used for DNA isolation; the remaining bloods were stored at -80oC for later use. 
 
 
2.2.2. Determination of X-chromosome inactivation status 
 
For determination of XCI status, HUMARA assay was used (Figure 2.2). Isolated 
DNAs were digested by methylation-sensitive enzyme HpaII. After incubation with HpaII, 
the sites on the active X-chromosome (checkered) will be cleaved, since they are 
unmethylated; the sites on the inactive X will not be cleaved, since they are methylated. 
Amplification by PCR between these primers will only yield a product from the uncleaved 
inactive X-chromosome. The X-inactivation patterns are therefore assessed in a female who is 
informative at the CAG repeat. The maternal and paternal alleles are resolved using PAGE 
(polyacrylamide gel electrophoresis) The HUMARA alleles are shown as single bands, for 
graphic clarity. In practice, each allele is represented by two major and two or more minor 
bands (Allen et al., 1992).   
 
 A 280-bp PCR amplification unit including the flanking HpaII sites and the 
trinucleotide repeat element (nucleotides 229-508) was developed for the human androgen-
receptor locus (Figure 2.3).  
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Figure 2.2.   Analysis of X-chromosome inactivation patterns by HUMARA assay.  The flow 
diagram illustrates expected results from DNA isolated from cell populations showing either 
random (left) or nonrandom (right) X-inactivation patterns. M and P = maternal and paternal 
X-chromosomes, respectively; (CAG)m and (CAG)p = allele associated with the polymorphic 
CAG repeat on the maternal and paternal X-chromosomes, respectively. (Allen et al., 1992).    
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Chromosome: X; Location: Xq11.2-q12 Gene: AR 
 
 
 
 
 
 
 
>ref|NC_000023.9|NC_000023:66680599-66860844 Homo sapiens chromosome X, 
reference assembly 
 
GGGAAAAAGGGCCGAGCTAGCCGCTCCAGTGCTGT ACAGGAGCCGAAGGGACGCACCACGCCAGCCCCA 
 
GCCC GGCTCCAGCGACAGCCAACGCCTCTTGCAGCGCGGCGGCTTCGAAGCCGCCGCCC GGAGCTGCC 
 
CTTTCCTCTTCGGTGAAGTTTTTAAAAGCTGCTAAAGACTCGGAGGAAGCAAGGAAAGTGCCTGGTAGGA 
CTGACGGCTGCCTTTGTCCTCCTCCTCTCCACCCCGCCTCCCCCCACCCTGCCTTCCCCCCCTCCCCCGT 
CTTCTCTCCCGCAGCTGCCTCAGTCGGCTACTCTCAGCCAACCCCCCTCACCACCCTTCTCCCCACCCGC 
CCCCCCGCCCCCGTCGGCCCAGCGCTGCCAGCCCGAGTTTGCAGAGAGGTAACTCCCTTTGGCTGCGAGC 
GGGCGAGCTAGCTGCACATTGCAAAGAAGGCTCTTAGGAGCCAGGCGACTGGGGAGCGGCTTCAGCACTG 
CAGCCACGACCCGCCTGGTTAGGCTGCACGCGGAGAGAACCCTCTGTTTTCCCCCACTCTCTCTCCACCT 
CCTCCTGCCTTCCCCACCCCGAGTGCGGAGCCAGAGATCAAAAGATGAAAAGGCAGTCAGGTCTTCAGTA 
GCCAAAAAACAAAACAAACAAAAACAAAAAAGCCGAAATAAAAGAAAAAGATAATAACTCAGTTCTTATT 
TGCACCTACTTCAGTGGACACTGAATTTGGAAGGTGGAGGATTTTGTTTTTTTCTTTTAAGATCTGGGCA 
TCTTTTGAATCTACCCTTCAAGTATTAAGAGACAGACTGTGAGCCTAGCAGGGCAGATCTTGTCCACCGT 
GTGTCTTCTTCTGCACGAGACTTTGAGGCTGTCAGAGCGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCT 
TCTCTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGCAGCGACTACCGCATCATCACAGCCTGTTGAACTCT 
TCTGAGCAAGAGAAGGGGAGGCGGGGTAAGGGAAGTAGGTGGAAGATTCAGCCAAGCTCAAGGATGGAAG 
TGCAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGCCGTCCAAGACCTACCGAGGAGCTTTCCAGAATCT 
 
GTTCCAGAGCGTGCGCGAAGTGATCCAGAACCC GGGCCCCAGGCACCCAGAGGCCGCGAGCGCAGCACC 
 
TCCC GGCGCCAGTTTGCTGCTGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA 
 
GCAGCAGCAGCAGCAGCAGCAGCAAGAGACTAGCCCCAGGCAGCAGCAGCAGCAGCAGGGTGAGGATGGT 
 
TCTCCCCAAGCCCATCGTAGAGGCCCCACAGGCTACCTGGTCCTGGATGAGGAACAGCAACCTTCACAGC 
 
CGCAGTCGGCCCTGGAGTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGCCGCCGTGGCCGCCAG 
CAAGGGGCTGCCGCAGCAGCTGCCAGCACCTCC GGACGAGGATGACTCAGCTGCCCCATCCACGTTGTC 
 
CCTGCTGGGCCCCACTTTCCCC GGCTTAAGCAGCTGCTCCGCTGACCTTAAAGACATCCTGAGCGAGGC 
 
CAGCACCATGCAACTCCTTCAGCAACAGCAGCAGGAAGCAGTATCCGAAGGCAGCAGCAGCGGGAGAGCG 
AGGGAGGCCTCGGGGGCTCCCACTTCCTCCAAGGACAATTACTTAGGGGGCACTTCGACCATTTCTGACA 
ACGCCAAGGAGTTGTGTAAGGCAGTGTCGGTGTCCATGGGCCTGGGTGTGGAGGCGTTGGAGCATCTGAG 
TCCAGGGGAACAGCTTCGGGGGGATTGCATGT ACGCCCCACTTTTGGGAGTTCCACCCGCTGTGCGTCC 
 
 
 
Fıgure 2.3   The sequence of AR, exon 1. The region amplified by PCR, the HpaII digestion 
sites and CAG repeat regions are shown.  
RS7 (Reverse Primer) 
CAG Repeats 
RS6 (Forward Primer) 
RsaI 
RsaI 
HpaII HpaII 
HpaII 
HpaII 
HpaII 
HpaII 
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2.2.2.1.  DNA Isolation 
 
The DNA isolation was carried out from 200 µl bloods via Nucleospin® Blood kit 
(Macherey-Nagel Inc., PA, USA) according to manufacturer’s instructions. The remaining 
bloods were stored at -80oC for later use. 
 
The concentration of the DNA was checked by spectrophotometric reading and 
horizontal 1% agarose gel electrophoresis in 1X TAE buffer. The DNA samples were loaded 
on gel after mixing with 6X loading buffer. 1 µg/ml ethidium bromide was added for 
visualization. After the run, the DNA samples were visualized with UV transilluminator.  The 
spectrophotometric reading was done in order to check the quality and quantity of the DNA. 
Ratio of 260/280 reading of 1.8 ± 0.2 was accepted as high quality DNA. In addition, 1% 
agarose gel electrophoresis verifies that the DNA is high-molecular weight. 
 
 
2.2.2.2. Restriction Enzyme Digestion 
 
Restriction enzyme digestion was carried out from 5 µl genomic DNA isolated from 
the bloods in 20 µl reaction volumes in 500 µl tubes. Methylation specific HpaII and RsaI 
enzymes were used for determination of X-inactivation status. The undigested control 
samples were only digested with RsaI enzyme using the conditions and materials (reaction 
buffer and BSA) given in the manufacturer’s instructions. One unit from each enzyme was 
used for the reaction. The digestion reactions were incubated at 37oC in the incubator for 
overnight. 
 
Undigested     Digested 
 
DNA  5.0 µl    DNA  5.0 µl 
Buffer  2.0 µl    Buffer  2.0 µl 
RsaI  0.2 µl    RsaI  0.2 µl 
ddH2O  12.8 µl    HpaII  0.8 µl 
      ddH2O  12.0 µl 
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2.2.2.3.  Polymerase chain reaction (PCR) 
 
7 µl template DNA (100-150 ng) was used in 25 µl PCR reaction containing 1X PCR 
buffer(10X), 1 µl MgCl2 (1.5 mM), 0.3 µl dNTPs (10 mM), 0.5 µl (20 pmol) from each primer 
and 0.2 µl Taq DNA Polymerase (5U). And ddH2O. Amplification was done using The 
GeneAmp System 9600 (Perkin-Elmer, USA) under following conditions:  
 
Initial denaturation at 95°C for 5 min, 30 cycles of 95°C for 30 sec (denaturation), 
58°C for 30 sec (annealing), 72°C for 30 sec (extension) and a final extension at 72°C for 5 
min.  
 
 
2.2.2.4.  Agarose gel electrophoresis  
 
PCR products were run in the 1.5% agarose gel by using 1X TAE.  
 
Agarose was completely dissolved in 1X TAE electrophoresis buffer to required 
percentage in microwave and ethidium bromide was added to final concentration of 30ng/ml.  
 
The samples were loaded onto agarose gel with 1/5 volume of loading buffer. The gel 
was run in 1X TAE at different voltage and time depending on the size of the fragment at 
room temperature. 
 
 
2.2.2.5.  Polyacrylamide gel electrophoresis (PAGE) 
 
The working PCR products were run in the 8% Polyacrylamide Gel 
 
8% PAGE 
Acrylamide: Bisacrylamide (29:1) 40 ml 
10x TAE    15 ml 
10% APS    1.5 ml 
TEMED    100 µl 
ddH2O     93.5 ml 
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The polyacrylamide solution was poured into the vertical apparatus and the digests 
were run at different W, and time, depending on the number of gels in 1X TAE buffer. After 
the run the gels were stained with EtBr for 10 minutes, washed with ddH2O for 10 minutes.  
 
 
2.2.2.6.   Densitometric Analysis 
 
Densitometric analysis of the alleles was performed using Multi-Analyst software 
version 1.1 (Bio-Rad, Hercules, CA). A corrected ratio (CrR) was calculated by dividing the 
ratio of the predigested sample (upper/lower allele) by the ratio of the nonpredigested sample 
for normalization of the ratios that were obtained from the densitometric analyses. 
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CHAPTERIII: RESULTS 
3.1.  PCR-based X-inactivation study of peripheral blood 
 
Androgen receptor assay was performed in order to determine the XCI patterns in the 
JIA patients and healthy controls, as explained in the methods section. Methylated inactive X-
chromosome is resistant to digestion by methylation specific HpaII enzyme, while 
unmethylated X-chromosome can be digested. Androgen receptor assay is used for XCI status 
detection; because there are highly polymorphic triplet repeats adjacent to the methylation site 
in the androgen receptor, which provide difference in lengths of the alleles. The concentration 
difference of more than 80% between the two alleles is considered as skewed XCI (Allen et 
al., 1992; Naumova et al., 1996). 
 
We studied XCI patterns of 72 JIA female patients, 183 female controls. The control 
group comprised newborns (n=91) and children with no history of an autoimmune condition 
(n=92). XCI pattern was informative in 56 of the 72 JIA patients, 52 of 91 newborn and 72 of 
92 children healthy controls (Appendices). The individuals, who do not show significant 
difference between two alleles were considered uninformative since only those whose alleles 
resolve adequately for densitometric analyses were included in the study. In Figure 3.1, 
patients with uninformative, random and skewed XCI patterns are shown. Sample 06-15 
shows uninformative XCI pattern as there is no significant difference between alleles, while 
samples 06-16 and 06-17 are informative as both alleles can be seen.   
 
Densitometric analysis is described in the methods section. By densitometric analysis, 
sample 06-17 was determined as having random XCI pattern, while the sample 06-16 has 
extremely skewed XCI pattern (Figure 3.1). 
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Figure 3.1   X-chromosome inactivation status in JIA patients. Lane 2-3: 06-15; lane 4-5: 06-
16; lane 6-7: 06-17. Polymerase chain reaction products from the androgen receptor 
methylation assay demonstrate random XCI patterns in sample 06-17 (allele ratio 51%:49%), 
and skewed patterns in sample 06-16 (93%:7%). The sample 06-15 is not informative for the 
androgen receptor polymorphism. For each sample, DNA was either undigested ( ) or 
digested (+) with the methylation-sensitive restriction enzyme HpaII. Lane 1: Marker ( pUC 
mix 8, 242-bp fragment is visible). 
 
 
Skewed XCI (>80% skewing) was observed in 14 of the 56 patients (25%) (Table 3.1), 
and 12 of the 124 controls (9.7%). Extremely skewed XCI, defined as >90% inactivation of 
one allele, was present in 9 patients (16.1%), and in only 4 controls (3.2%, P=0.002, 
OR=16.9, 95% CI 6.2-45.8) (Appendices).  
 
 
 
 
 
 
 
 
 
 
 
                          06-15                   06-16         06-17             
             
   HpaII            +     -         + -    +       -  
 
 
    1        2           3   4      5         6             7 
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Table 3.1  Proportion of the JIA patients and controls with skewed XCI 
 
 
Degree of skewing (%) No. (%) observed with skewing 
    JIA patients (n=56)   Controls (n=124) 
90+    9 (16.1)    4 (3.2) 
80-89    5 (8.9)     8 (6.5) 
70-79    12 (21.4)    28(22.6) 
60-69    15 (26.8)    37 (29.8) 
50-59    15 (26.8)    47 (37.9) 
 
For comparison by χ2, P= 0.006 (>80% skewing); P= 0.002 (>90% skewing) 
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CHAPTER IV: DISCUSSION 
A reduction in the sex ratio (male: female) is the characteristic of the most 
autoimmune diseases (Whitacre, 2001).  For several years candidate mechanisms that could 
be important in pathogenesis have been uncovered. Nowadays, there are some explanations 
for the female predominance in autoimmune diseases. These include genetic traits associated 
with autoimmunity (Rioux and Abbas, 2005), pregnancy related microchimerism (Adams and 
Nelson, 2004), and disturbances of XCI in female subjects (Stewart, 1998). 
 
In this study we demonstrate skewed XCI patterns (>80:20) in peripheral blood 
mononuclear cells of a significant proportion (25%) of females with JIA. 11.1% of female 
healthy children control subjects demonstrate skewed X-inactivation patterns, while 7.6% of 
female newborn control subjects had skewed XCI pattern. When extremely skewed XCI is 
concerned (>90:10), the results are more distinctive: 16.1% of the JIA patients have extremely 
skewed XCI, while 2.8% of the healthy children, and 3.8% healthy newborn controls have 
skewed XCI.  When we take all control subjects together, we found the frequency of controls 
with extremely skewed XCI as 3.2% (OR=16.9 95% CI 6.2-45.8). This is consistent with the 
findings in the world, which change 1%-6% (OR 4-6) (Chitnis et al., 2000; Buller et al., 1999; 
Lanasa et al., 1999; Sangha et al., 1999). Our results suggest that skewed XCI is associated 
with the pathogenesis of JIA. Previously in our group, association between skewed XCI and 
SSc and AITD was shown. To the best of my knowledge, this is the first time that an 
association between skewed XCI and a pediatric disease is observed. 
 
There are several mechanisms that are used in order to determine XCI pattern, such as 
protein isoforms and transcription based methods.  The exonic polymorphisms, which are 
used to identify the X-chromosome, are typically non-synonymous mutations. A variety of 
genes are used to determine XCI status including G6PD (Prchal and Guan, 1993), IDS 
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(iduronate-2-sulfatase) (Gregg et al., 2000; el-Kassar et al., 1997), MPP1 (also known as p55) 
(Luhovy et al., 1995), BTK (Bruton tyrosine kinase), and FHL-1 (4.5 LIM domain 1) (Liu et 
al., 2003). In this study we used HUMARA assay, which is based on DNA methylation and 
tandem CAG repeats. The HUMARA assay is more widely used than protein isoform and 
transcription based methods because of the variable number of CAG nucleotide repeats 
allowing most patients to be informative for the assay.  In our study we had a limited number 
of patients, as we used only specific subtypes that have female predominance. Therefore, it is 
important to have all patients informative for the assay. From 72 patients, 56 were informative 
for CAG repeats in AR, while 124 of 183 controls were informative. It would be helpful to 
use the genes above for the patients and controls that are not informative for CAG repeats in 
AR.  
 
There are mainly two reasons for skewed XCI: primary and secondary. When there is 
a mutation in XIST (X-inactive- specific transcript) and Xic, it is called primary cause (Puck, 
1998). The secondary causes are deleterious X-linked mutations, X-chromosome 
rearrangements, aging, twinning, or monoclonal expansion of cells (Brown, 1999). Here we 
propose that as a secondary cause, a putative lethal mutation on the X-chromosome may result 
in a cell-survival disadvantage.  Cells that carry a putative lethal mutation in their active X do 
not survive because of the mutation, causing loss of mosaicism.  
 
Because of this survival disadvantage, skewed XCI occurs. The self antigens on the 
inactive X of these cells are not presented in the thymus or in other peripheral sites. Because 
of an unknown mechanism, at a later stage of the life, these self antigens encounter the 
lymphocytes. Therefore, these self antigens are recognized as non-self and cause 
autoimmunity. 
 
 
4.1.   Future Perspective 
 
 In order to prove our loss of mosaicisim hypothesis, we are going to conduct a 
comprehensive genomic study by using high-density microarray analysis. We searched for all 
genes and nonsynonymous single nucleotide polymorphisms (SNPs) on the X-chromosome 
using NCBI and Ensembl databases.  After elimination of the redundancies, we identified 
2715 nonsyn+syn SNPs, and 7277 intronic SNPs with the heterozygosity value between 0.40 
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and 0.50.  The flanking regions of these SNPs were compiled through the use of an algorithm. 
At the end, we had 1141 coding synonymous + 1725 coding nonsynonymous + 4 coding not 
determined, totally 2870 coding SNPs which corresponds to 783 genes. 2802 intronic SNPs 
which corresponds to 160 genes. With this study, we will analyze copy number variation and 
allele frequencies of heterozygous genes.  For this study, we will use all the autoimmune 
diseases studied in our lab, including JIA, and healthy controls. 
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CHAPTER VII. APPENDICIES 
Appendix A  The list of JIA patients and their XCI pattern 
 
 
Number  Sample XCI Pattern 
90+ 16.10%   
1 1 06-029 100 
2 2 05-069 100 
3 3 05-188 95 
4 4 06-014 95 
5 5 05-180 95 
6 6 06-013 95 
7 7 06-016 93 
8 8 06-030 92 
9 9 06-008 90 
80-89 8.90%   
10 1 05-179 88 
11 2 06-026 84 
12 3 06-018 81 
13 4 05-064,05-186 80 
14 5 06-020 80 
70-79 21.40%   
15 1 05-170 78 
16 2 06-012 76 
17 3 05-071 75 
 49 
18 4 05-178 75 
19 5 06-021 75 
20 6 06-052 74 
21 7 05-187 73 
22 8 05-183 72 
23 9 06-009 71 
24 10 06-043 71 
25 11 05-065 70 
26 12 05-063 70 
60-69 26.80%   
27 1 05-070 69 
28 2 06-025 69 
29 3 05-601 64 
30 4 05-173 63 
31 5 05-182 63 
32 6 06-024 62 
33 7 06-037 62 
34 8 06-044 62 
35 9 05-602 61 
36 10 06-028 61 
37 11 05-073 60 
38 12 05-072 60 
39 13 05-062 60 
40 14 06-051 60 
41 15 05-066 60 
50-59 26.80%   
42 1 05-168 58 
43 2 06-034 57 
44 3 05-167 56 
45 4 05-169 56 
46 5 06-038 56 
47 6 05-177 55 
48 7 06-019 54 
 50 
49 8 06-027 53 
50 9 06-031 53 
51 10 06-048 52 
52 11 05-166 51 
53 12 05-185, 06-17 51 
54 13 06-046 51 
55 14 06-045 50 
56 15 06-053 50 
NI 22.20%   
57 1 05-067 NI 
58 2 05-068 NI 
59 3 05-171, 06-15 NI 
60 4 05-172 NI 
61 5 05-174 NI 
62 6 05-175 NI 
63 7 05-176 NI 
64 8 05-181 NI 
65 9 05-184 NI 
66 10 06-007 NI 
67 11 06-022 NI 
68 12 06-023 NI 
69 13 06-032 NI 
70 14 06-033 NI 
71 15 06-035 NI 
72 16 06-036 NI 
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Appendix B   The list of healthy children controls and their XCI pattern 
 
 
Number Sample XCI Pattern 
90+ 2.80%   
1 1 05-332 100 
2 2 06-072 100 
80-89 8.30%   
3 1 05-583 88 
4 2 05-370 85 
5 3 05-369 85 
6 4 06-056 85 
7 5 06-071 82 
8 6 05-588 82 
70-79 22.2   
9 1 06-057 79 
10 2 06-070 78 
11 3 05-595 75 
12 4 06-077 75 
13 5 05-587 75 
14 6 05-348 75 
15 7 05-359 75 
16 8 05-599 75 
17 9 06-068 75 
18 10 05-375 73 
19 11 05-372 73 
20 12 06-066 73 
21 13 05-342 72 
22 14 06-059 70 
23 15 05-354 70 
24 16 06-069 70 
60-69 27.80%   
25 1 05-347 68 
 52 
26 2 05-331 67 
27 3 05-585 66 
28 4 05-360 65 
29 5 05-592 65 
30 6 05-357 64 
31 7 05-366 64 
32 8 05-364 63 
33 9 05-596 63 
34 10 05-356 62 
35 11 05-581 62 
36 12 06-074 62 
37 13 06-081 62 
38 14 05-350 61 
39 15 05-374 61 
40 16 05-377 61 
41 17 06-075 61 
42 18 06-061 60 
43 19 05-591 60 
44 20 05-339 60 
50-59 38.90%   
45 1 05-341 58 
46 2 05-358 58 
47 3 05-367 58 
48 4 05-582 58 
49 5 05-594 58 
50 6 06-058 58 
51 7 05-333 57 
52 8 05-351 57 
53 9 05-346 57 
54 10 06-078 56 
55 11 06-060 55 
56 12 05-337 55 
57 13 05-355 55 
 53 
58 14 05-368 55 
59 15 05-586 55 
60 16 05-338 55 
61 17 05-336 55 
62 18 06-067 55 
63 19 05-349 54 
64 20 05-584 54 
65 21 05-329 53 
66 22 05-593 53 
67 23 05-363 51 
68 24 06-080 51 
69 25 05-590 50 
70 26 05-343 50 
71 27 05-598 50 
72 28 06-079 50 
NI 21.70%   
73 1 05-330 NI 
74 2 05-344 NI 
75 3 05-345 NI 
76 4 05-361 NI 
77 5 05-362 NI 
78 6 05-365 NI 
79 7 05-371 NI 
80 8 05-373 NI 
81 9 05-376 NI 
82 10 05-379 NI 
83 11 05-589 NI 
84 12 05-600 NI 
85 13 06-055 NI 
86 14 06-062 NI 
87 15 06-065 NI 
88 16 06-073 NI 
89 17 06-076 NI 
 54 
90 18 05-353 NI 
91 19 05-378 NI 
92 20 05-352 NI 
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Appendix C   The list of health newborn children and their XCI pattern 
Numbers                     Samples XCI Pattern 
90+ 3.30%   
1 1 06-830 100 
2 2 06-848 99 
80-89 3.80%   
3 1 06-863 82 
4 2 06-865 80 
70-79 23.10%   
5 1 06-837 78 
6 2 06-850 78 
7 3 06-875 78 
8 4 06-868 77 
9 5 06-896 77 
10 6 06-823 75 
11 7 06-824 75 
12 8 06-801 75 
13 9 06-805 75 
14 10 06-893 72 
15 11 06-843 71 
16 12 06-844 70 
60-69 32.70%   
17 1 06-797 68 
18 2 06-889 68 
19 3 06-870 67 
20 4 06-851 66 
21 5 06-862 66 
22 6 06-838 65 
23 7 06-900 65 
24 8 06-882 65 
25 9 06-827 64 
26 10 06-881 63 
27 11 06-877 62 
 56 
28 12 06-884 62 
29 13 06-820 61 
30 14 06-847 61 
31 15 06-811 61 
32 16 06-826 60 
33 17 06-804 60 
50-59 36.50%   
34 1 06-891 59 
35 2 06-810 58 
36 3 06-831 58 
37 4 06-869 58 
38 5 06-864 57 
39 6 06-883 57 
40 7 06-871 55 
41 8 06-836 55 
42 9 06-873 54 
43 10 06-888 54 
44 11 06-846 53 
45 12 06-845 52 
46 13 06-878 52 
47 14 06-860 51 
48 15 06-876 50 
49 16 06-832 50 
50 17 06-874 50 
51 18 06-880 50 
52 19 06-822 50 
NI 42.90%   
53 1 06-840 NI 
54 2 06-839 NI 
55 3 06-814 NI 
56 4 06-800 NI 
57 5 06-802 NI 
58 6 06-803 NI 
 57 
59 7 06-807 NI 
60 8 06-809 NI 
61 9 06-812 NI 
62 10 06-813 NI 
63 11 06-815 NI 
64 12 06-821 NI 
65 13 06-825 NI 
66 14 06-828 NI 
67 15 06-829 NI 
68 16 06-841 NI 
69 17 06-842 NI 
70 18 06-849 NI 
71 19 06-861 NI 
72 20 06-866 NI 
73 21 06-867 NI 
74 22 06-872 NI 
75 23 06-879 NI 
76 24 06-885 NI 
77 25 06-886 NI 
78 26 06-887 NI 
79 27 06-890 NI 
80 28 06-892 NI 
81 29 06-894 NI 
82 30 06-895 NI 
83 31 06-897 NI 
84 32 06-898 NI 
85 33 06-899 NI 
86 34 06-799 NI 
87 35 06-808 NI 
88 36 06-816 NI 
89 37 06-817 NI 
90 38 06-819 NI 
91 39 06-818 NI 
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Appendix E   The PAGE figures of XCI patterns of JIA patients 
 
 
GEL1 
 
 
 
 
GEL2 
 
 
 
 
GEL3 
 
 
 
 
 
 
 
 
 
 
 
 
    M                               05-166         05-167          05-168         05-169          05-170 
            51:49            56:44            58:42           56:44            78:22 
        
        M     05-171        05-172       05-173        05-174        05-175         05-176 
                            NI               NI              63:37            NI              NI                 NI 
    M          05-177             05-178              05-179             05-180              05-181 
                  55:45                 75:25                88:12                95:5                    NI 
 59 
GEL4 
 
 
 
 
 
GEL5 
 
 
 
 
 
GEL6 
 
 
 
              
 
 
 
 
 
 
 
 
 
 M         05-64               05-65           05-66           05-67            05-68           05-70 
               80:20                70:30          R(60:40)        NI                  NI              69:31 
  M        05-71           05-182          05-183         05-184          05-185            05-186 
              75:25            63:37             72:28              NI              51:49               80:20 
   M           05-62               05-63               05-69               05-72                05-73 
                  60:40               70:30               100:0               60:40                 60:40 
 60 
GEL7 
 
 
 
GEL8 
 
 
 
 
 
 
GEL9 
 
 
 
 
GEL10 
 
 
   M             05-186                  05-187                  05-188                   05-173 
                     80:20                     73:27                      95:5                      63:37 
 M         06-7              06-8             06-9            06-12           06-13              06-14 
              NI                 90:10            71:29           76:24            95:5               95:5        
M                                                                                                                  05-602 
            61:39 JIA controls 
 M               05-601 
                 64:36 
JIA controls 
 61 
 
GEL11 
 
 
 
 
GEL12 
 
 
 
 
GEL13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       M        06-15            06-16         06-17            06-18          06-19             06-20 
                    NI                 93:7           51:49            81:19          54:46             80:20 
 M          06-21          06-22            06-23          06-24          06-25          06-26 
               75:25            NI                 NI              62:38          69:31           84:16 
      06-27                06-28                06-29                 06-30                06-31   
      53:47                 61:39                100:0                  92:8                 53:47           
 62 
GEL14 
 
 
 
 
 
GEL15 
 
 
 
 
 
GEL16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 M             06-33                 06-34                 06-35              06-36                  
                    NI                    57:43                    NI                   NI                                 
      06-41              06-43              06-44               06-45                 06-46 
       NW                71:29               62:38               50:50                 51:49 
    06-48                          06-51                         06-52                            06-53          
    52:48                           60:40                         74:36                             50:50 
 63 
GEL17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M          06-32            06-37             06-38            06-61             06-63               06-80 
               NI                62:38            56:44 
JIA  controls 
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Appendix F   The PAGE figures of XCI patterns of healthy controls 
 
 
GEL1 
 
 
 
 
 
GEL2 
 
 
 
 
 
GEL3 
 
 
 
 
 
 
 
 
 
   M         05-334           05-335          05-337          05-339          05-341           05-342 
                  NW                 NW            55:45             60:40            58:42            72:28 
        
  M       05-343            05-344         05-345          05-346          05-347          05-349 
              50:50                NI                 NI              57:43             68:32            54:46 
      
  M        05-329            05-330           05-331          05-332           05-333            05-336 
               53:47                NI                67:33            100:0             57:43                 NW 
                  R(55:45) 
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GEL4 
 
 
 
 
GEL5 
 
 
 
 
 
GEL6 
 
 
 
 
 
GEL7 
 
 
 
 M       05-338           05-344          05-345          05-346         05-347          05-348 
             55:45               NI                 NI               57:43            68:32            75:25 
M            controls of JIA                  05-349            05-350          05-351          05-352 
                54:46              61:39            57:43               NI 
    M       05-353         05-354         05-355         05-356         05-357           05-358 
                NI                70:30            55:45           62:38           64:36            58:42 
  M       05-359         05-360        05-361        05-363          05-364         05-365  
              75:25           65:35            NI              51:49            63:37              NI 
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GEL8 
 
 
 
 
 
GEL9 
 
 
 
 
 
 
GEL10 
 
 
 
 
 
 
 
 
 
 
  M       05-366         05-368          05-369         05-370         05-371        05-372 
              64:36           55:45             85:15           85:15             NI             73:27 
 M          05-336               05-362              05-367               05-373              05-374 
                55:45                   NI                   58:42                   NI                    61:39 
 M          05-375              05-376               05-377               05-378              05-379 
                73:27                  NI                     61:39                   NI                     NI 
 67 
GEL11 
 
 
 
 
GEL12 
 
 
 
 
 
GEL13 
 
 
 
 
 
 
 
 
 
 
  M        05-582           05-583           05-584         05-585           05-586          05-587 
               58:42             88:12              54:46            66:34            55:45             75:25 
 M        05-588           05-589          05-592          05-593           05-594          05-595 
              82:18                NI              65:35             53:47             58:42            75:25 
M           05-596              05-598              05-599             05-600             05-602 
                63:37                50:50                 75:25                NI                   61:39 
                         JIA patient 
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GEL14 
 
 
 
 
 
GEL15 
 
 
 
 
 
 
GEL16 
 
 
 
 
 
 
 
 
 
 
 M                                                      05-581         05-590           05-591           05-601 
                                                           62:38            50:50             60:40              64:36 
                                   JIA patient 
   M        06-65            06-66             06-67          06-68             06-69            06-70 
                NI                73:27             55:45           75:25             70:30            78:22 
   M             06-71                06-72                 06-73                06-74                06-75  
                    82:18                100:0                   NI                    62:38                61:39       
 69 
GEL17 
 
 
 
 
GEL18 
 
 
 
 
GEL19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 M         06-55            06-56              06-57             06-58            06-59             06-60 
                NI               85:15               79:21             58:42            70:30             55:45  
M         06-62              06-64              06-76            06-77             06-78               06-79 
              NI                    NW                 NI               75:25              56:44               50:50 
M          06-32            06-37             06-38            06-61             06-63             06-80 
                         60:40              98:2              51:49 
              R(NW) 
JIA patients 
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Appendix G   The PAGE figures of XCI patterns of healthy newborns 
 
 
GEL1 
 
 
 
 
 
 
GEL2 
 
 
 
 
 
 
GEL3 
 
 
 
 
 
 
GEL4 
 
 
 
 
 
 
 
 
 
 
 M     06-797        06-798       06-800        06-801        06-802       06-803       06-806 
          100:0           100:0            NI            NI                NI              NI               NI 
         R(68:32)       R(NW) 
M    06-807        06-809        06-810        06-812        06-813       06-814       06-815 
           NI             NI              58:42            NI                NI               NI               NI 
M      06-799        06-800       06-801        06-802        06-803         06-804       06-805 
            NI                NI            75:25             NI              NI                60:40        75:25 
M      06-807         06-808        06-811        06-814        06-816        06-817         06-819 
             NI              NI               61:39            NI               NI               NI             NI 
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GEL5 
 
 
 
 
 
GEL6 
 
 
 
 
 
GEL7 
 
 
 
 
 
GEL8 
 
 
 
 
 
 
GEL9 
 
 
 
 
 
 
 
  M        06-797           06-810          06-812         06-813           06-815        06-818 
   68:32    58:42      NI  NI         NI      NI 
   M          06-820             06-821               06-823           06-824              06-825 
       61:39         NI           75:25           75:25                 NI 
  M         06-826            06-829               06-830           06-831              06-832 
     60:40         NI         100:0       58:42           50:50 
M       06-797             06-810            06-812          06-813           06-815           06-818 
           68:32                58:42                 NI                   NI                  NI                  NI 
      06-820                 06-821                06-823                 06-824                06-825 
        61:39                   NI                      75:25                    75:25                      NI 
 72 
GEL10 
 
 
 
 
 
 
GEL11 
 
  
 
 
 
GEL12 
 
 
 
 
 
 
GEL13 
 
 
 
 
 
 
GEL14 
 
 
 
  06-826              06-829               06-830             06-831              06-832 
    60:40                   NI                   100:0               58:42                 50:50 
   06-836        06-837       06-838        06-839        06-840        06-841        06-842 
     99:1           78:22          65:35          95:5             98:2               NI               NI 
   R(55:45)       R(NI)          R(NI) 
 06-843        06-845       06-846       06-847        06-849       06-850       06-851 
   71:29           52:48        53:47          61:39            NI            78:22         66:34    
 06-860        06-861        06-862        06-863        06-864        06-865         06-866 
  51:49             NI              66:34         82:18           57:43         80:20               NI   
 06-867          06-868         06-869          06-870           06-871           06-872          
     NI               77:23            58:42            67:33             55:45                NI 
 73 
GEL15 
 
 
 
 
 
GEL16 
 
 
 
 
 
 
GEL17 
 
 
 
 
 
 
GEL18 
 
 
 
 
 
 
 
GEL19 
 
 
 
 
 
 
 06-873         06-874          06-875          06-876            06-877         06-878 
   54:46           50:50             78:22           50:50               62:38           52:48          
 06-879            06-880            06-881             06-882            06-883            06-884  
     NI                50:50               63:37              65:35               57:43              62:38 
 06-885         06-886          06-887          06-888            06-889          06-890 
     NI                 NI                 NI              54:46             68:32                NI 
 06-891         06-892        06-893         06-894        06-896         06-897 
   59:41              NI            72:38              NI            77:23               NI 
 06-899            06-900             06-822              06-827              06-828          
     NI                 65:35               50:50                 64:36                  NI 
 74 
GEL20 (repeat for checking) 
 
 
 
 
 
 
 
GEL21 (repeat for checking) 
 
 
 
 
 
GEL22 (repeat for checking) 
 
 
 
 
   06-797       06-801      06-805        06-806       06-822        06-830      06-836 
    68:32          75:25         75:25           NW           50:50          100:0        55:45 
   
 06-839       06-840      06-844        06-848      06-863       06-865       06-875 
    NI               NI           70:30          99:1           82:18           80:20        78:22 
   
 06-881      06-895      06-898 
  63:37           NI              NI 
   
